drugset / Trial / NCT03486626

Endometrial Thickness and Subendometrial Vascularity in Anovulatory Polycystic Ovarian Syndrome Patients Treated by Metformin

NCT03486626 ↗

Phase 4 Unknown 85 enrolled Ain Shams Maternity Hospital
NaSingle-groupOpen-labelTreatment

Summary

The participants will receive metformin 500mg 3times per day for 3months and one month is left for spontaneous pregnancy to occur or not (primary outcome ) and the investigators will check endometrial thickness and subendometerial vascularity as markers of endometrial receptivity before and after the treatment.

Timeline

Start
2018-01-02
Primary completion
2018-09
Completion
2018-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 500 mg —